Understanding the impact of amyloid beta targeted therapies on biomarkers and clinical endpoints in Alzheimer's disease

• Published in: Alzheimer's & dementia : translational research & clinical interventions Vol. 11; no. 2; pp. e70069 - n/a
• Main Authors: Petersen, Ronald C., Graf, Ana, Atkins, Alexandra S., Brys, Miroslaw, Murphy, Jennifer, Miller, David S., Reyderman, Larisa, Siemers, Eric, Smith, Janice, Carrillo, Maria C., Weber, Christopher J.
• Format: Journal Article
• Language: English
• Published: United States John Wiley and Sons Inc 01.04.2025; Wiley
• Subjects: Alzheimer's disease; amyloid beta protein; clinical meaningfulness; cognitive function; dementia; Research Roundtable; amyloid beta protein; cognitive function; clinical meaningfulness; dementia; Research Roundtable; Alzheimer's disease

The Alzheimer's disease (AD) scientific field continues to make significant advances in early detection and treatments, which importantly rest on advances in our fundamental understanding of AD pathobiology and its contribution to cognitive decline. Clinical readouts of monoclonal antibodies ag...